Entera Bio Ltd (ENTX)

2.270 -0.170 (-6.97%)
Real-time Cboe USD Disclaimer

Entera Bio Ltd Company Profile

Equity Type
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company’s product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Contact Information
Jerusalem,9112002 Israel
972 2 532 7151
Top Executives
Gerald M. Lieberman 75 2014 Independent Chairman of the Board
Yonatan Malca 56 2011 Independent Director
Gerald M. Ostrov 73 2019 Independent Director
Ron Mayron 59 2021 Independent Director
Miranda J. Toledano 45 2018 CEO & Director
Roger J. Garceau 69 2016 Director
Arthur C. Santora 73 2018 Member of Scientific Advisory Board
Sean Ellis 49 2019 Independent Director
Haya Taitel 61 2023 Independent Director
Steven R. Goldstein 73 2023 Member of Clinical & Scientific Advisory Board
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.